Abbisko Cayman (STU:8ZD) EBITDA Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Abbisko Cayman EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abbisko Cayman's EBITDA for the six months ended in Dec. 2023 was €-27.30 Mil. Abbisko Cayman's Revenue for the six months ended in Dec. 2023 was €0.00 Mil. Therefore, Abbisko Cayman's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.

Abbisko Cayman EBITDA Margin % Historical Data

The historical data trend for Abbisko Cayman's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman EBITDA Margin % Chart

Abbisko Cayman Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-7,922.27

-2,156.17

Abbisko Cayman Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBITDA Margin %	Get a 7-Day Free Trial			-6,284.87	-	-	-1,040.66	-

Competitive Comparison of Abbisko Cayman's EBITDA Margin %

For the Biotechnology subindustry, Abbisko Cayman's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Abbisko Cayman's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's EBITDA Margin % falls into.

Abbisko Cayman EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Abbisko Cayman's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-52.783	/	2.448
	=	-2,156.17 %

Abbisko Cayman's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-27.304	/	0
	=	%

Abbisko Cayman (STU:8ZD) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Abbisko Cayman EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Abbisko Cayman (STU:8ZD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (STU:8ZD) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

02256:Hong Kong

Address

Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN

Website

https://www.abbisko.com

Abbisko Cayman Ltd is a investment holding company it operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.

Abbisko Cayman (STU:8ZD) Headlines

No Headlines